| Literature DB >> 35990347 |
Rutika R Jagtap1, Aniket Garud2, Shubhangi S Puranik1, Mithun Rudrapal2, Mohammad Azam Ansari3, Mohammad N Alomary4, Meshal Alshamrani5, Ahmad Salawi5, Yosif Almoshari5, Johra Khan6,7, Bhagyashri Warude2.
Abstract
Nanobiotechnology is a burgeoning field of research with applications in cancer treatment, targeted chemotherapy, and molecular diagnosis. This study aims at the fabrication of silver nanoparticles using embelin derived from Embelia ribes to evaluate its anticancer property. Silver nanoparticles (AgNPs) have emerged as a novel nano-carrier for therapeutic agents with a wide range of medical capabilities due to their unique structural, physicochemical, and optical features. In our study, the particle size of fabricated AgNPs was measured as 25 nm, and the zeta potential was recorded as -5.42 mV, which indicates the good stability of embelin-derived AgNPs. The crystalline surface morphology was observed by SEM analysis. The FT-IR spectrum confirmed the reduction in silver ions (Ag+) by embelin, and the TEM analysis exhibited polydispersed Ag+ of 20-30 nm. The anticancer potential of embelin-fabricated AgNPs was investigated using in vitro studies on lung cancer cells by the MTT assay. The results revealed significant dose-dependent inhibition of cell proliferation against A549 cell lines. Embelin AgNP-induced apoptosis was measured by the annexin-V PI apoptosis assay, which exhibited significantly low necrotic cells as compared to apoptotic cells. Finally, the findings of our study suggest the anticancer potential of biofabricated embelin AgNPs, particularly against lung cancer cells.Entities:
Keywords: MTT assay; anticancer; apoptosis assay; biofabrication; embelin; lung cancer; silver nanoparticles
Year: 2022 PMID: 35990347 PMCID: PMC9386231 DOI: 10.3389/fnut.2022.960674
Source DB: PubMed Journal: Front Nutr ISSN: 2296-861X
Figure 1Chemical structure of embelin.
Figure 2FESEM images of embelin-derived AgNP. (A) 1 μm and (B) 100 nm.
Figure 3TEM images of embelin-derived AgNP. (A) 100 nm and (B) 20 nm.
Figure 4Cell viability by MTT assay. A549 cells treated with embelin AgNPs.
Figure 5Apoptosis occurred in (A) control cells, (B) embelin AgNP-treated cells, and (C) doxorubicin (standard)-treated cells at a concentration of 6 μg/ml. Quadrants are as follows: Q1, necrotic cells; Q2, late apoptotic cells; Q3, viable cells; and Q4, early apoptotic cells.
Figure 6Annexin PI assay for apoptosis analysis. Emb, embelin; Doxo, doxorubicin.